IRCT20200105046010N107尚未招募Unknown
In-vivo Bioequivalence Study of Azithromycin 500 mg Capsules of The Test Drug (ZITHROSAD 500 mg Cap., Sajjad Darou, Iran) in Compared with The Reference Drug (ZITHROMAX® 500 mg. Cap. Pfizer, Ireland) In Iranian Healthy Volunteers
Sajad darou shargh0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index 18-28 kg/m^2
- •consent Age of 18-55 years old
- •Informed consent
排除标准
- •Nicotine consumption
- •history Cardiovascular disease
- •History Liver and kidney
- •history Alcohol and opioid addiction
- •Allergy reactions history to Azithromycin
研究者
相似试验
尚未招募
不适用
Bioequivalence study of Azithromycin 500 mg tabletIn the present study, no diseases will be examined and products will be administered by healthy volunteers..IRCT20210519051345N4Tabriz University of Medical Sciences24
尚未招募
不适用
Investigating the in vivo bioequivalence of Azithromycin 250 mg capsuleIRCT20210519051345N13Tabriz University of Medical Sciences24
已完成
不适用
Bioequivalence study of Azithromycin 200 mg/5mL powder for oral suspension in healthy Thai volunteer under fasting conditioTCTR20180109003All Research Co., Ltd.42
已完成
不适用
Bioequivalence study of Azithromycin 500 mg tabletThis study is performed on healthy volunteers..IRCT20200623047902N13Sanamed pharma company24
招募中
不适用
In-vivo Bioequivalence study of Azithromycin capsules 250 mg with brand drugs (ZITHROMAX® 250 mg Pfizer, Ireland)IRCT20200105046010N37Kharazmi Pharmaceutical Co24